This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Micron Technology, RCI Hospitality, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Micron Technology, RCI Hospitality, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
Stock Market News for Dec 9, 2020
by Zacks Equity Research
U.S. stocks closed higher on Tuesday as investors¿¿¿ sentiment got a boost from positive news on the COVID-19 vaccine front that overshadowed worries of surging coronavirus cases and a record number of hospitalizations, and slow progress in the sanction of another financial aid.
Pfizer (PFE) Pneumococcal Vaccine BLA Gets FDA's Priority Tag
by Zacks Equity Research
Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.
5 Materials Stocks to Make the Most of Economic Recovery
by Zacks Equity Research
U.S. economy is poised for a rebound on positive COVID-19 vaccine developments and hopes of a fiscal stimulus, making it prudent to invest in stocks like Bunge (BG) and Cabot (CBT) from the materials sector.
Next Chapter in Covid-19 Era Underway
by Mark Vickery
Aside from sub-zero refrigeration requirements, the Pfizer-BioNTech vaccine looks to be first in line and among the highest efficacy rates possible.
Productivity Increases in Q3
by Zacks Equity Research
Productivity Increases in Q3
Moderna (MRNA) to Supply More Doses of COVID-19 Vaccine to Canada
by Zacks Equity Research
Moderna (MRNA) announces deal to supply 20 million additional doses of its COVID-19 vaccine candidate, mRNA-1273, to the Canadian Government, upon potential approval. The total tally is now 40 million doses.
Markets Find Vaccine-Rally Equilibrium; AZO Mixed in Q1
by Mark Vickery
Great Britain injects its first Pfizer (PFE)-BioNTech (BNTX) vaccine patients today, marking a momentous occasion whereby the world may soon return to pre-pandemic activities.
Pfizer (PFE) Up 14% in 3 Months on COVID-19 Vaccine Progress
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is now approved for emergency use in United Kingdom and Bahrain.
Markets Hit Record Highs, Promise Further Growth: 5 Top Picks
by Zacks Equity Research
Promising vaccine news and hopes of further fiscal stimulus helped benchmark indexes to close at record highs, making this a prudent time to invest in names like Cabot (CBT) and Forestar (FOR)
6 S&P 500 Must-Buy Stocks for 2021 Flying High Amid Pandemic
by Nalak Das
It will be prudent to invest in Zacks top-Ranked S&P 500 stocks that have skyrocketed year to date with strong potential for 2021. These include DE, HOLX, LB, PKI, IPGP, QRVO.
Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.
5 Mid-Cap Stocks That Became Top Large Caps Amid Pandemic
by Nalak Das
We have narrowed our search to five mid-cap stocks that have become large caps during the coronavirus hit past eight and a half months. These are: SAM, LB, PKI, UI, GNRC.
The Vaccines Are Here. Are We Out of the Woods Now?
by John Blank
It almost seems like we are just an appointment at the doctor's office away from opening up our economy again.
BioNTech (BNTX) Surges: Stock Moves 6.2% Higher
by Zacks Equity Research
BioNTech (BNTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Stock Market News for Dec 3, 2020
by Zacks Equity Research
U.S. stock markets closed modestly higher on Wednesday as investors await fresh round of fiscal stimulus.
5 Stocks to Buy at Deep Discount for a Stronger Portfolio
by Nalak Das
Discounted stock price and a favorable Zacks Rank will be the right combination to strengthen one's portfolio in the near future. These stocks include PHM, LEN, SAM, W, DT.
Oil Ends Higher on Vaccine News Despite EIA's Bearish Report
by Nilanjan Choudhury
The top five gainers of the S&P 500 in November were all energy firms - Occidental Petroleum (OXY), Devon Energy (DVN), Apache (APA), Diamondback Energy (FANG) and TechnipFMC (FTI).
CrowdStrike (CRWD) Beats, Snowflake (SNOW) Mixed in Q3
by Mark Vickery
Cyberintelligence security firm CrowdStrike surged well ahead of estimates on every metric in its Q3 report, while fledgling enterprise software firm Snowflake missed on its bottom line.
Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More
by Zacks Equity Research
Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.
Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.
Encouraging News on COVID-19 Vaccine
by Zacks Equity Research
Encouraging News on COVID-19 Vaccine
ADP Reports 307K New Jobs, Revisions Up
by Mark Vickery
307K new private-sector jobs was lower than expected, and beneath the upwardly revised 404K from October.
Stock Market News for Dec 2, 2020
by Zacks Equity Research
U.S. stock markets closed higher on Tuesday on the back of optimism surrounding COVID-19 vaccine.
Pfizer/BioNTech Seek Marketing Nod for COVID-19 Vaccine in EU
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.